key: cord-0858299-uusketnl
authors: Crowell, Trevor A.; Daud, Ibrahim I.; Maswai, Jonah; Owuoth, John; Sing’oei, Valentine; Imbach, Michelle; Dear, Nicole; Sawe, Fred; Eller, Leigh Anne; Polyak, Christina S.; Ake, Julie A.
title: Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March 2020
date: 2021-11-15
journal: AIDS
DOI: 10.1097/qad.0000000000003054
sha: 9de34d2479b4de702b19c3e51642466c08979958
doc_id: 858299
cord_uid: uusketnl

Among 582 participants in Western Kenya who were retrospectively tested from January through March 2020, 19 (3.3%) had detectable SARS-CoV-2 antibodies. The prevalence of detectable SARS-CoV-2 antibodies was similar between participants with and without HIV (3.1% vs. 4%, P = 0.68). One participant reported a cough in the preceding week but others denied symptoms. These may represent cross-reactivity or asymptomatic infections that predated the first reported COVID-19 cases in Kenya.

Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay. J Clin Virol 2021; 139:104820. 20. Rubio-Acero R, Castelletti N, Fingerle V, Olbrich L, Bakuli A, W€ olfel R, et al. In search of the SARS-CoV-2 protection correlate: head-to-head comparison of two quantitative S1 assays in precharacterized oligo-/asymptomatic patients. Infect Dis Ther 2021. doi:10.1007/s40121-021-00475-x. 21. Mueller T. Antibodies against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals with and without COVID-19 vaccination: a method comparison of two different commercially available serological assays from the same manufacturer. See related paper on page 2391 denied symptoms. These may represent crossreactivity or asymptomatic infections that predated the first reported COVID-19 cases in Kenya.

The global pandemic of coronavirus disease-19 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has overwhelmed national health systems in many countries. Although the African continent was predicted to be particularly vulnerable, African populations appear to have thus far evaded widespread morbidity and mortality because of COVID-19 [1] . Kenya's first identified COVID-19 case was a 27-year-old woman who traveled from the United States to Nairobi. Her diagnosis on 12 March 2020 immediately prompted nationwide mitigation efforts. Still, the infection spread from her to other airline passengers and, within 2 weeks, COVID-19 infections had been confirmed in five counties including and surrounding Nairobi and Mombasa [2] . This timeline for geographic spread suggested that the local outbreak emanated from arriving travelers at two major ports of entry. However, data from other countries suggest that SARS-CoV-2 was circulating weeks or months before initial cases were detected [3] [4] [5] . We retrospectively tested stored serum specimens from people with and without HIV in Western Kenya for evidence of potential SARS-CoV-2 circulation or cross-reactivity before the first Kenyan case was reported in March 2020.

The ongoing African Cohort Study (AFRICOS) enrolls adults with and without HIV in an approximately 5 : 1 ratio in four countries [6] . Seven hospital-based clinics in Kisumu and Kericho, Kenya, provided samples for these analyses. Cohort procedures include 6-monthly medical history-taking, physical examination, and laboratory assessments that include CD4 þ T-cell count and HIV RNA quantification for people with HIV (PWH) [7] . At each visit, participants are asked about symptoms in the preceding week. Medical records and laboratory studies are reviewed to identify comorbidities, including some potentially associated with adverse COVID-19 outcomes [6] .

Because of the emerging COVID-19 outbreak, study visits were paused on 19 March 2020 [8] . For these analyses, stored serum from 1 January 2020 through 19 March 2020 was retrospectively tested using the Platelia SARS-CoV-2 Total Ab assay (Bio-Rad Laboratories, Hercules, California, USA) to qualitatively detect anti-SARS-CoV-2 nucleocapsid IgM, IgA, and/or IgG. Samples with signal-to-cutoff ratio (S/CO) at least 0.8 on initial testing were retested in duplicate; one or two retest results with S/CO at least 1.0 was considered positive. For each participant with detectable antibodies, stored serum from the preceding study visit (as early as June 2019) was also tested.

A total of 582 participants underwent retrospective testing, including 508 (87.3%) PWH and 327 (56.2%) women.

Participants had a median age of 43.3 (interquartile range 35.7-51.6) years. Nineteen (3.3%) had detectable SARS-CoV-2 antibodies (Table 1) , including seven who also had a positive test at their preceding visit and 12 who did not (Supplemental Figure, http://links.lww.com/QAD/ C264). The prevalence of detectable SARS-CoV-2 antibodies was similar between participants with and without HIV (3.1% vs. 4%, P ¼ 0.68).

Our sites in rural Western Kenya are far removed from the urban centers of Nairobi and Mombasa where SARS-CoV-2 was believed to have been introduced into Kenya. However, these sites are near substantial infrastructure development projects, such as highway construction backed by Chinese government and commercial entities. Some of the earliest known cases of COVID-19 in Africa were imported by manufacturing workers who traveled from China to Egypt [9] , and it is possible that SARS-CoV-2 could have reached the otherwise remote region of our study similarly via construction workers. Expectedly, the seroprevalence estimates in this study were lower than those reported from African settings later in the pandemic, including a 4.3% seroprevalence among Kenyan blood donors in June 2020 that increased to 9.1% by September 2020 [10] .

However, it is likely that some or all of the positive assays in our study were because of cross-reactivity from preexisting antibodies or causes other than SARS-CoV-2, particularly among participants who were serofast from previous visits that substantially predated the emerging COVID-19 pandemic. Although small studies showed no cross-reactivity between the Platelia assay and common alpha or beta coronaviruses (package insert, Bio-Rad Laboratories 16008597, 2020/06), variations in assay performance based on target antigen and study population limit the ability to compare data across studies and to assert that all positive assays in our study represented true SARS-CoV-2 infections [11] . Recent work has suggested that serologic cross-reactivity is significantly more common in samples from Africa than other settings, documenting prepandemic cross-reactive antibodies to the SARS-CoV-2 nucleocapsid protein among approximately one out of six samples tested in Tanzania [12] .

Participants with detectable SARS-CoV-2 antibody were almost universally asymptomatic, despite some having risk factors for adverse outcomes of infection. Importantly, our study predominantly enrolls PWH and, accordingly, most cases of detectable SARS-CoV-2 antibodies were observed amongst PWH. The absence of any severe clinical cases of COVID-19 among these individuals is consistent with a growing body of literature that well controlled HIV is not a risk factor for adverse outcomes of SARS-CoV-2 infection [13] . If participants in our study did have asymptomatic infection, then such cases could have contributed to early undetected spread of the pandemic in Kenya. If such participants had preexisting cross-reactive antibodies, then partial immunity to SARS-CoV-2 could potentially explain the lower than predicted morbidity and mortality due to COVID-19 in Africa.

In conclusion, we present serologic data indicating either cross-reactivity or asymptomatic infections that predated the first reported COVID-19 cases in Kenya. Further research is needed to distinguish the two possible explanations for detectable SARS-CoV-2 antibodies in our study. This finding improves our understanding of early COVID-19 epidemiology and may help to predict its future course in Africa, thereby informing resource allocation and COVID-19 response policy. Stored serum samples collected from 1 January 2020 through 19 March 2020 from participants at seven sites in Kenya were tested retrospectively using the Platelia SARS-CoV-2 Total Ab assay to detect anti-SARS-CoV-2 IgM, IgA, and/or IgG. Of 582 participants tested, 19 had detectable antibodies against SARS-CoV-2, with participant and testing characteristics summarized above. For each participant with detectable antibodies, serologic testing was also performed on stored serum from the immediately preceding study visit to evaluate for interval seroconversion, with a negative or equivocal prior test interpreted as 'seroconverted' (12 participants) and a positive prior test interpreted as 'serofast' (7 participants; see Supplemental Figure Comorbid conditions included any of the following: cancer, renal insufficiency, respiratory disease, heart conditions, sickle cell disease, hyperglycemia, asthma, elevated blood pressure, neurologic conditions, immunocompromised state, pregnancy, tobacco smoking. BP, blood pressure.

COVID-19 among people living with HIV: a systematic review

COVID-19 outcomes among persons living with or without diagnosed HIV infection in New York State

COVID-19 in immunocompromised hosts: what we know so far

Durability of responses after SARS-CoV-2 mRNA-1273 vaccination

Safety and immunogenicity of two RNAbased Covid-19 vaccine candidates

High antibody response to twodose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases (in press)

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients

Glucocorticoids and B Cell depleting agents substantially impair immunogenicity of mRNA vaccines to SARS-CoV-2

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Vaccination in HIV-infected adults

Safety and antibody response to the first dose of SARS-CoV-2 messenger RNA vaccine in persons with HIV

The REDCap consortium: building an international community of software platform partners

Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases

Variation in SARS-CoV-2 outbreaks across sub-Saharan Africa

Covid-19: three more cases confirmed bringing total to 31

Retrospective detection of SARS-CoV-2 in symptomatic patients prior to widespread diagnostic testing in Southern California

SARS-CoV-2 has been circulating in northern Italy since December 2019: evidence from environmental monitoring

Antibodies to SARS-CoV-2 in All of Us Research Program Participants

Noninfectious comorbidity in the African cohort study

Persistent low-level viremia predicts subsequent virologic failure: is it time to change the third 90?

Transient reductions in HIV clinic attendance and food security during the COVID-19 pandemic for people living with HIV in four African countries

How coronavirus disease 2019 entered Africa and the Middle East: a case study from Egypt

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors

Challenges in interpreting SARS-CoV-2 serological results in African countries

High prevalence of preexisting serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Saharan Africa

COVID-19 and HIV infection co-pandemics and their impact: a review of the literature